|
||||||||||||||||||
|
|
||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq. DescriptionThe HI100 monoclonal antibody reacts with human CD45RA, a 220 kDa molecule expressed by subpopulations of CD4+ peripheral T lymphocytes, CD8+ peripheral T lymphocytes, and B cells. The CD45RA+ T cell populations are mainly naive/virgin allowing the use of HI100 mAb as a phenotypic marker to discriminate T cell subsets. Applications ReportedFor research use only, not for diagnostic or therapeutic use. The HI100 antibody has been reported for use in flow cytometric analysis, and immunohistochemical staining. Applications TestedThe HI100 antibody has been tested by flow cytometric analysis of human peripheral blood leukocytes. This can be used at less than or equal to 0.5 μg per 100 μl blood (or per 1 million cells in 100 μl total staining volume). It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. References
Knapp, W., B. Dorken, et al. eds. (1989). Leucocyte Typing IV: White Cell Differentiation Antigens. Oxford University Press. New York. Related ProductsCat. 11-4011 FITC Anti-Mouse IgG Cat. 13-4013 Biotin Anti-Mouse IgG (clone Polyclonal) Cat. 11-4317 Streptavidin-FITC (Fluorescein isothiocyanate) Cat. 12-4317 Streptavidin-PE (Phycoerythrin) Cat. 17-4317 Streptavidin Allophycocyanin (SA-APC) Cat. 14-4732 Affinity Purified Mouse IgG2b Isotype Control Cat. 11-9979 FITC anti-human CD45RA (clone JS-83) Cat. 12-9979 PE anti-human CD45RA (clone JS-83) Cat. 13-9979 Biotin anti-human CD45RA (clone JS-83) Cat. 14-9979 Affinity Purified anti-human CD45RA (clone JS-83) Cat. 15-9979 PE-Cy5 anti-human CD45RA (clone JS-83) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
![]() |
|
Copyright © 2000-2008 eBioscience, Inc. Product For Research Use Only: Not for further distribution without written consent. |